Previously, Clarke served as the company’s chief scientific officer and vice president of research and development, where he was involved in developing iCALM and iSPERSE technologies, designed for delivering single and combination therapeutics of inhaled dry powder drug products.
In the new role, Clarke will be responsible for advancing iCALM inhaled drug candidates in human clinical trials for chronic respiratory diseases including chronic obstructive pulmonary disease and cystic fibrosis.
Pulmatrix chief executive officer Robert Clarke said the company has the potential to develop multiple novel product opportunities from its iSPERSE platform including the advancement of proprietary iCALM therapies through clinical trials.
"I am excited to take on this leadership role at Pulmatrix at such a pivotal time, as we advance our novel platform and therapeutics with breakthrough potential to address unmet needs of patients with chronic respiratory diseases," Clarke added.